MarketBeat
15 Aug 2026, 09:02 UTC · 9w ago
Impact · against what's priced in
MDGL is showing strong commercial momentum with a $1.3B run rate and a strategic pivot toward combination therapies to defend its MASH moat. The lack of cannibalization from Wegovy and the potential to double the TAM via F4 disease expansion provide meaningful upside catalysts.
No priced-in read yet
What the story claims
5 claims · scored −1 bearish … +1 bullish
Madrigal reported Q2 2026 revenue of $364 million, a 71% year-over-year increase, with a trailing-12-month run rate of approximately $1.3 billion.
More positive than 99% of claims this week
Successful outcomes in the ongoing MAESTRO-NASH Outcomes study for F4 disease could potentially double Rezdiffra's addressable market.
So whatExpanding the indication to include approximately 245,000 F4 compensated-cirrhosis patients represents a massive increase in total addressable market (TAM).
Continue reading
5 related stories
The company has achieved a $1.3B trailing-12-month run rate with 50,000+ active patients, while effectively neutralizing the threat of Wegovy, which accounts for less than 1% of specialist prescriptions for MASH.
Read from the article alone
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 98% of claims this week
Madrigal reports that Novo Nordisk's Wegovy has had no significant negative impact on Rezdiffra sales, noting less than 1% of Wegovy prescriptions are written by specialists for MASH.
More positive than 88% of claims this week
The company has expanded its pipeline to 10 assets, including a GLP-1 agonist (MGL-2086) and a DGAT-2 inhibitor, intended for combination use with Rezdiffra.
More positive than 81% of claims this week
European sales are expected to remain negligible in 2026 due to reimbursement hurdles and U.S. administration policy uncertainties.
More negative than 75% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
Reported strong commercial growth for Rezdiffra, a 71% revenue increase, and a positive outlook for its development pipeline.
Near neutral — 92% of ticker scores this week are stronger
Mentioned as a competitor with Wegovy, but Madrigal states it has not had a significant negative impact on their sales.
Near neutral — 92% of ticker scores this week are stronger
Mentioned as the company that licensed ervogastat to Madrigal, with no material financial impact reported.
Near neutral — 92% of ticker scores this week are stronger
Mentioned as the company that licensed an siRNA targeting PNPLA3 to Madrigal.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
58m ago
More positive than 31% of relationship scores this week
[a_to_b] Madrigal licensed an siRNA targeting PNPLA3 from Arrowhead Pharmaceuticals.
More positive than 13% of relationship scores this week
[mutual] Madrigal's Rezdiffra competes with Novo Nordisk's Wegovy in the MASH market.
−7.9%
Price is moving against the score
$467.54 vs $507.56 close before publication (Aug 14) · not market-adjusted
MDGL chart →
